

SUPPLEMENTARY MATERIAL

Three Monthly Injections Versus One Initial Injection of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: Twelve-Month Results of a Prospective Randomized Study

Wenyi Tang^{#1,2,3}, Jingli Guo^{#4}, Gezhi Xu^{1,2,3}, Wei Liu^{*1,2,3}, Qing Chang^{*1,2,3}

¹Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, China

²Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai, China

³NHC Key Laboratory of Myopia (Fudan University); Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, China

⁴Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Wenyi Tang and Jingli contributed equally to the work.

***Correspondence:** Qing Chang, PhD, Department of Ophthalmology, Eye and ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China, E-mail: qngchang@aliyun.com.
Phone:86-21-64377134.

Or Wei Liu, PhD, Department of Ophthalmology, Eye and ENT Hospital of Fudan University, 83 Fenyang Road, Shanghai 200031, China, E-mail: Bfgf2020@163.com. Phone:86-21-64377134.

Figure S1. Flowchart showing patient randomisation and study completion in the 3+PRN and 1+PRN groups. N, number of patients; PRN, pro re nata




Table S1. Ocular Adverse Events in Patients with BRVO According to Treatment Regimen (3+PRN or 1+PRN)

	3+PRN (n = 35)	1+PRN (n = 34)	<i>P</i>
Conjunctival haemorrhage	3 (8.6)	3 (8.8)	-
Eye pain	2 (5.7)	1 (2.9)	-
Foreign body sensation	2 (5.7)	1 (2.9)	-
IOP transiently increased	1 (2.9)	1 (2.9)	-
Vitreous floaters	1 (2.9)	1 (2.9)	-
Total (%)	9 (25.7)	7 (20.6)	0.77

BRVO branch retinal vein occlusion, *PRN* pro re nata, *IOP* intraocular pressure